MDGLMEDIUM SIGNALFINANCIAL10-K

MDGL showed meaningful operational improvement with substantially reduced losses while building commercial capabilities following Rezdiffra's regulatory approval.

The company appears to be transitioning from pure development to commercialization, evidenced by the substantial expansion in SG&A expenses alongside meaningfully improved operating performance. The language changes emphasize post-marketing commitments and reimbursement challenges, indicating focus has shifted to commercial execution risks rather than development uncertainties.

Comparing 2026-02-19 vs 2025-02-26View on EDGAR →
FINANCIAL ANALYSIS

MDGL's financial position reflects a company in commercial transition, with cash nearly doubling to $199M while current liabilities grew substantially, likely reflecting increased commercial infrastructure investments. Operating losses improved meaningfully alongside a substantial expansion in SG&A expenses, suggesting increased commercial spending is beginning to drive operational efficiency. The overall picture signals a biotech company moving from development losses toward potential profitability, though cash burn remains significant despite improvement.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+98.7%
$100.0M→$198.7M

Cash position surged 98.7% — strong cash generation or capital raise providing significant financial cushion.

SG&A Expense
P&L
+87.1%
$435.1M→$813.8M

SG&A up 87.1% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Current Liabilities
Balance Sheet
+83.3%
$169.3M→$310.3M

Current liabilities surged 83.3% — significant near-term obligations; verify ability to meet short-term debt.

Capital Expenditure
Cash Flow
-68.1%
$1.5M→$467K

Capex reduced 68.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Cash Flow
Cash Flow
+58.4%
-$455.6M→-$189.6M

Operating cash flow surged 58.4% — exceptional cash generation, highest quality earnings signal.

Operating Income
P&L
+39.7%
-$497.9M→-$300.1M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Net Income
P&L
+38.1%
-$465.9M→-$288.3M

Net income grew 38.1% — bottom-line growth signals improving overall business health.

Total Assets
Balance Sheet
+20.9%
$1.0B→$1.3B

Asset base grew 20.9% — expansion through organic growth, acquisitions, or capital deployment.

Current Assets
Balance Sheet
+20.6%
$1.0B→$1.2B

Current assets grew 20.6% — improving short-term liquidity or inventory/receivables build.

Stockholders Equity
Balance Sheet
-20.1%
$754.4M→$602.7M

Equity decreased 20.1% — buybacks or losses reducing book value, monitor solvency ratios.

LANGUAGE CHANGES
NEW — 2026-02-19
PRIOR — 2025-02-26
ADDED
As of February 12, 2026, the registrant had 22,939,969 shares of common stock outstanding.
You should not place undue reliance on any such forward-looking statements.
You should carefully consider all of the information in this report and, in particular, the following principal risks and all of the other specific factors described in Item 1A.
of this report, Risk Factors, before deciding whether to invest in our company.
We obtained accelerated approval in the United States and conditional marketing authorization in the European Union ( EU ) for Rezdiffra, and we are subject to certain post-marketing commitments.
+7 more — sign up free →
REMOVED
As of February 21, 2025, the registrant had 22,080,246 shares of common stock outstanding.
You should not place undue reliance on any such forward-looking statements, which speak only as of the date they are made.
Before you invest in our securities, you should read the following summary together with the more detailed description of material risks described in the section titled Risk Factors in Part I, Item 1A of this Annual Report and the other information contained in this Annual Report.
We obtained regulatory approval of Rezdiffra in the United States through an accelerated approval process, and we are subject to certain post-marketing commitments.
We may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →